Search Result

Results for "

SAH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Autophagy (1) Carbonic Anhydrase (1) Caspase (1) Cathepsin (2) CHIKV (1) Cytochrome P450 (1) Dengue Virus (1) DNA Methyltransferase (2) DNA/RNA Synthesis (1) Endogenous Metabolite (7) ERK (1) Exosomes (1) GABA Receptor (1) HBV (1) Histone Methyltransferase (2) HSV (1) Lipoxygenase (1) MEK (1) Melanocortin Receptor (2) Methionine Adenosyltransferase (MAT) (1) MMP (2) Nucleoside Antimetabolite/Analog (3) Parasite (1) Ras (2) Reactive Oxygen Species (ROS) (1) Reference Standards (2) SARS-CoV (4) Small Interfering RNA (siRNA) (1) SOS1 (2) TGF-beta/Smad (2) TGF-β Receptor (2) Trk Receptor (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (4) Infection (8) Inflammation/Immunology (6) Metabolic Disease (10) Neurological Disease (10)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (1) Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10999

Trametinib Maximum Cited Publications 286 Publications Verification GSK1120212; JTP-74057	MEK Autophagy Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis, cross the blood-brain barrier (BBB), used in research related to subarachnoid hemorrhage (SAH) .

HY-19528

*SAH* 15+ Cited Publications SAH (S-Adenosylhomocysteine)	Endogenous Metabolite	Metabolic Disease
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-W010347

L-Homocysteine 5+ Cited Publications	Endogenous Metabolite Cathepsin	Cardiovascular Disease Inflammation/Immunology
L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia .

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 15+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-111310

ML351 2 Publications Verification	Lipoxygenase	Neurological Disease Metabolic Disease
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .

HY-B0553

Methazolamide 4 Publications Verification L584601	Carbonic Anhydrase Apoptosis Reactive Oxygen Species (ROS) Caspase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a K_i of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage .

HY-136144

FIDAS-5 5+ Cited Publications	Methionine Adenosyltransferase (MAT)	Cancer
FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities .

HY-122816

HLY78 10+ Cited Publications	Wnt β-catenin Apoptosis	Cardiovascular Disease Neurological Disease Cancer
HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research .

HY-19528S

SAH-d4 SAH (S-Adenosylhomocysteine)-d₄	Endogenous Metabolite	Metabolic Disease
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-P1726

MSG606	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 can delay pain hypersensitivity and reduce cholesterol levels. MSG606 can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-18684

SIBA 5'-Isobutylthioadenosine; 5'-Deoxy-5'-isobutylthioadenosine	Nucleoside Antimetabolite/Analog HSV Parasite	Infection Metabolic Disease Cancer
SIBA (5'-Isobutylthioadenosine) is a transmethylation inhibitor (SAH (HY-19528) analogue), with potent anti-proliferative activity. SIBA reversibly inhibits the production of HSV-1 by blocking methylation, specifically by blocking the 5' end-capping of viral mRNA. SIBA also inhibits the growth of tumour cells in vitro and metastatic spread in vivo. SIBA can be used in cancer, HSV-1 infection and anti-malaria studies .

HY-149048

Adenosylhomocysteinase SAHH; AHCY	Exosomes Endogenous Metabolite HBV	Infection Metabolic Disease
Adenosylhomocysteinase (SAHH; AHCY) is a highly conserved enzyme. Adenosylhomocysteinase reversible catalyzes S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. The serum exosomal Adenosylhomocysteinase level can be used as a prognostic biomarker in HBV-LC patients .

HY-101446

HIOC	Trk Receptor ERK Apoptosis	Neurological Disease
HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 15+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P2265A

SAH-SOS1A TFA	SOS1 Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-19528R

SAH (Standard) SAH (S-Adenosylhomocysteine) (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .

HY-136145

FIDAS-3	Wnt	Cancer
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC₅₀ of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities .

HY-P10359A

TAT-QFNP12 acetate	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 acetate is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

HY-W010347R

L-Homocysteine (Standard)	Reference Standards Endogenous Metabolite Cathepsin	Cardiovascular Disease Inflammation/Immunology
L-Homocysteine (Standard) is the analytical standard of L-Homocysteine. This product is intended for research and analytical applications. L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia[1][2].

HY-170524

TDI-015051	SARS-CoV DNA Methyltransferase Cytochrome P450	Infection
TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC₅₀ values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the K_a value against SARS-CoV-2 is 0.061 nM .

HY-P2265

SAH-SOS1A	SOS1 Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-19528S2

SAH-13C10	Endogenous Metabolite	Metabolic Disease
SAH- ¹³C₁₀ is the ¹³C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-133135

CHIKV-IN-1	CHIKV Nucleoside Antimetabolite/Analog	Infection
CHIKV-IN-1 (Compound 3a) is a compound that inhibits the Chikungunya virus (CHIKV) with an EC₅₀ of 0.12 μM. CHIKV-IN-1 is a potent inhibitor of the S-adenosyl-L-homocysteine hydrolase (SAH hydrolase), with an IC₅₀ of 0.36 μM. CHIKV-IN-1 is only effective against CHIKV and some other alphaviruses, but has no activity against other RNA viruses such as SARS-CoV, MERS-CoV, and ZIKV. CHIKV-IN-1 has extremely low cytotoxicity (CC₅₀ > 250 μM), and it has an extremely high selectivity index (SI > 2083). CHIKV-IN-1 can be used in research on anti-Chikungunya virus .

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 TFA is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 TFA can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 TFA can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 TFA can delay pain hypersensitivity and reduce cholesterol levels. MSG606 TFA can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-179249

Fluoroneplanocin A-8N	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog SARS-CoV Dengue Virus	Infection
Fluoroneplanocin A-8N (Compound 3a) is an inhibitor targeting SAH hydrolase (IC₅₀ = 1.51 μM) and viral RNA polymerase. Fluoroneplanocin A-8N exhibits broad-spectrum anti-SARS-CoV-2 and dengue virus activity, with EC₅₀ values of 12.2 and 37.4 μM respectively. Fluoroneplanocin A-8N has no cytotoxicity. Fluoroneplanocin A-8N can be used for anti-positive-strand viruses .

HY-P10359

TAT-QFNP12	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

HY-RS00207

ACSM3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ACSM3 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSM3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ACSM3 Human Pre-designed siRNA Set A ACSM3 Human Pre-designed siRNA Set A

HY-162177

SARS-CoV-2-IN-78	SARS-CoV	Infection
SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .

HY-170523

RU-0415529	SARS-CoV DNA Methyltransferase	Infection
RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC₅₀ of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models .

HY-W754627

Clazolam Isoquinazepon; SAH-1123	GABA Receptor	Neurological Disease
Clazolam (Isoquinazepon; SAH-1123) is a GABA Receptor modulator. Clazolam can be used in research on neurological diseases .

HY-180846

NT32	Histone Methyltransferase	Cancer
NT32 is a selective METTL13 stabilizer with a K_d value of 14 μM. NT32 could occupy both the SAM/SAH-binding pocket and the peptide substrate-binding site of METTL13 simultaneously. NT32 specifically targets and stabilizes METTL13. NT32 shows no inhibitory activity against non-small cell lung cancer .

Cat. No.	Product Name	Target	Research Area

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 15+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-P1726

MSG606	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 can delay pain hypersensitivity and reduce cholesterol levels. MSG606 can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 15+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P2265A

SAH-SOS1A TFA	SOS1 Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P10359A

TAT-QFNP12 acetate	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 acetate is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

HY-P2265

SAH-SOS1A	SOS1 Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 TFA is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 TFA can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 TFA can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 TFA can delay pain hypersensitivity and reduce cholesterol levels. MSG606 TFA can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-P10359

TAT-QFNP12	TGF-beta/Smad MMP	Neurological Disease
TAT-QFNP12 is a peptide that blocks the NDRG2-PPM1A binding and reduces Smad2/3 phosphorylation, decreases astrocytic MMP-9 production and BBB disruption after subarachnoid hemorrhage (SAH) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-19528

*SAH* 15+ Cited Publications SAH (S-Adenosylhomocysteine)	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Disease markers Metabolic Disease Amino acids Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-W010347

L-Homocysteine 5+ Cited Publications	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Cathepsin
L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia .

HY-149048

Adenosylhomocysteinase SAHH; AHCY	Infection Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Exosomes Endogenous Metabolite HBV
Adenosylhomocysteinase (SAHH; AHCY) is a highly conserved enzyme. Adenosylhomocysteinase reversible catalyzes S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. The serum exosomal Adenosylhomocysteinase level can be used as a prognostic biomarker in HBV-LC patients .

HY-19528R

SAH (Standard) SAH (S-Adenosylhomocysteine) (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Disease markers Amino acids Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .

HY-W010347R

L-Homocysteine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Cathepsin
L-Homocysteine (Standard) is the analytical standard of L-Homocysteine. This product is intended for research and analytical applications. L-Homocysteine, an amino acid, is a homocysteine that has L configuration. Homocysteine is an essential intermediate in normal mammalian metabolism of methionine. L-Homocysteine induces upregulation of Cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia[1][2].

Cat. No.	Product Name	Chemical Structure

HY-19528S

SAH-d4
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-19528S2

SAH-13C10
SAH- ¹³C₁₀ is the ¹³C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85414

	ACSM3 Antibody (YA5106) ACSM3; SAH; Acyl-coenzyme A synthetase ACSM3; mitochondrial; Acyl-CoA synthetase medium-chain family member 3; Butyrate--CoA ligase 3; Butyryl-coenzyme A synthetase 3; Middle-chain acyl-CoA synthetase 3; Protein SA homolog	WB, ICC/IF, IP, ELISA, IF-Tissue	Human, Mouse, Rat
	ACSM3 Antibody (YA5106) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ACSM3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-19528

*SAH* 15+ Cited Publications SAH (S-Adenosylhomocysteine)		Nucleoside Analogs Adenosine
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-RS00207

ACSM3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
ACSM3 Human Pre-designed siRNA Set A contains three designed siRNAs for ACSM3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SAH

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products